Pfizer has released mid-stage (Phase 2b) VESPER-3 results: its experimental drug PF’3944 (previously known as MET-097i and brought into Pfizer via the Metsera deal) helped people with obesity or overweight lose up to 12.3% of body weight (placebo-adjusted) by week 28. The headline feature is the dosing schedule: patients started with weekly injections during dose escalation, then switched to a once-monthly maintenance shot. Pfizer says there was no clear weight-loss “plateau” by week 28, and the trial continues through week 64.
Videos
The genre of the LLM interview emerged the moment the first model was released to the public. Since then, “artificial intelligence” has been asked to prophesy the future, debate the philosophical nature of being, or simply engage in heart-to-hearts. This creates the illusion of conversation with a sentient being — a phenomenon that simultaneously frightens, astonishes, and inspires awe. Yet, we have never encountered an interview where the AI is addressed honestly, with its mask of humanity stripped away.
Artificial intelligence has rapidly become a working tool in companies, government administration, education, and everyday services within just a few years. As AI becomes more…